News

Lack of access to effective treatments is forcing blood cancer patients to take desperate measures 12 April 2018 Lack of funded access to...

The IMF is very pleased to have established a partnership with AbbVie to conduct the largest, most comprehensive chart-review study of myeloma...

Multiple Myeloma action month March 2018: Thanks to medical innovation, Multiple Myeloma patients are living longer than ever before. Multiple...

What’s New in Myeloma Treatment: a New Zealand Perspective Dr. Leanne Berkahn, Dr. Henry Chan, Dr. Phillip Insull, and Dr. David Simpson, spoke at...

Improving Survival in Multiple Myeloma Dr. Henry Chan from North Shore Hospital spoke at our patient seminar on his recent work looking at multiple...

The Cancer Society is calling for major changes to cancer services to save lives. It says 2,500 more New Zealanders would have survived cancer if...

INVITATION Patient Seminar: CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Presented by Dr Rob Weinkove on 8 March, 5.30-7pm at...

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory...

We're keen to know how Myeloma New Zealand can help you. What you'd like to hear about on the website? What support you feel would be useful? We'd...

The FDA has granted bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma, according...